Official blog
Compliance-aware guides and brand updates for adult consumers.
Page 25 of 36 / 848 articles
IQOS—Philip Morris International's heated tobacco device—was supposed to be the centerpiece of the company's smoke-free transformation. A decade and billions of dollars later, the verdict is still out: is heated tobacco the future, or an expensive detour?
Emerging research suggests that the trillions of bacteria living in the human gut play a role in nicotine metabolism, craving intensity, and cessation success. The frontier of smoking cessation may run through the digestive tract.
As smoking rates plummet in high-income countries, they are rising—or declining much more slowly—across much of Africa, Asia, and the Middle East. The global cigarette epidemic is not ending. It's relocating.
Traditional cigarette advertising has been banned for decades in most countries. But on TikTok, Instagram, and YouTube, nicotine products—particularly flavored vapes and pouches—are reaching audiences that regulation was designed to protect, through channels that regulation never anticipated.
The WHO Framework Convention on Tobacco Control, adopted in 2003 and now ratified by 182 countries, is the legal backbone of global tobacco control. Two decades on, its record is mixed—and the debates it suppressed are re-emerging with new urgency.
Tobacco taxation is the single most effective policy tool for reducing smoking. But when taxes rise too high, too fast, or without complementary policies, they create black markets, regressive burdens, and political backlash that can undo decades of progress.
Anti-smoking stigma is intended to motivate quitting. But a growing body of evidence suggests it does the opposite—increasing stress, reducing self-efficacy, delaying quit attempts, and driving smokers away from the healthcare system they need.
The majority of smokers who try to quit attempt it without any assistance—no medication, no counseling, no nicotine replacement. The method has an estimated success rate of 3-5%. So why does 'going cold turkey' remain the default strategy?
Public health agencies have spent decades telling the public that 'there is no safe tobacco product.' That message saved millions of lives. It also makes it nearly impossible to communicate the truth about safer nicotine products without undermining the original message.
As disposable vapes face environmental backlash and potential bans, a quiet resurgence of open-system vaping—refillable tanks, rebuildable coils, custom mods—is reshaping the enthusiast market. The future of vaping may look more like its past.
Nicotine pouches—tobacco-free, spit-free, and discreet—have gone from a Scandinavian niche to the fastest-growing segment of the nicotine industry. The major cigarette companies are betting billions that pouches, not vapes, are their smoke-free future.
Nicotine is among the most stigmatized molecules in pharmacology—associated, in the public imagination, with cancer, addiction, and death. But the association confuses the drug with its most common delivery mechanism. Understanding the difference is the key to rational policy.
Despite decades of regulation, taxation, public education, and the rise of alternatives, over one billion people still smoke combustible cigarettes. The persistence of the cigarette is not a mystery—but the explanations challenge every comfortable narrative in tobacco control.
Adolescent nicotine exposure affects the developing brain in ways that adult exposure doesn't. The science is clear about the risks—but the policy implications are more contested than either side of the youth vaping debate acknowledges.
As global cigarette consumption declines, millions of smallholder tobacco farmers—concentrated in low-income countries—face an economic transition that nobody is funding, coordinating, or even acknowledging at scale.
FDA's Premarket Tobacco Product Application process was designed to bring order to the vaping industry. Instead, it created a two-tier market: a handful of authorized products from large corporations, and a vast, thriving underground of everything else.
Nicotine addiction is physiological, but 'being a smoker' is an identity—one built over years of rituals, social bonds, and self-narratives. Quitting means not just breaking a chemical dependency, but losing a version of yourself.
Machine learning models trained on millions of quit attempts are beginning to predict—with unsettling accuracy—who will succeed, when they'll relapse, and what intervention would help most. The science of quitting is becoming a science of prediction.
For decades, the public health establishment measured success by one metric: abstinence. But what if the biggest wins come from accepting that people will continue using nicotine—and making that use dramatically safer?
Behind every brightly-colored disposable vape is a global supply chain of extraction, assembly, consumption, and waste—one that produces millions of units of electronic waste every week, with no meaningful recycling infrastructure.
When Congress gave FDA authority over tobacco-derived nicotine, it inadvertently created a multibillion-dollar market for synthetic nicotine—made in labs, free from tobacco, and for a time, free from regulation.
One hundred articles, following one hundred before them. The second series concludes—not because the nicotine story is resolved, but because every inquiry must have an ending. The work continues.
A comprehensive, evidence-based summary of where we stand on nicotine policy—the evidence, the debates, the progress, and the remaining challenges.
Two hundred articles, two series, one continuous inquiry into the nicotine landscape. This final article closes the series—not with a conclusion, but with gratitude and an invitation.
Products
Select a product to view details, highlights, and technical specifications.
